Transcription of Evidence check - Agency for Clinical Innovation
{{id}} {{{paragraph}}}
Example: quiz answers
Evidence check - Agency for Clinical Innovation
COVID-19 Critical Intelligence Unit 28 April 2021 1 Evidence check 28 April 2021 Immunocompromised patients and COVID-19 vaccines Evidence check question What is the Evidence on COVID-19 vaccination for immunocompromised patients including risks and adverse events, efficacy and advice from professional colleges? In brief Evidence on COVID-19 vaccination in immunocompromised patients is limited. Small studies suggest that immunosuppression may be associated with attenuated immune response to SARS-CoV-2 in some patients after the first (1-3) and second vaccine dose.(4-7) o A pre peer review publication in haemodialysis patients showed dialysis patients had significantly lower SARS-COV-2 S antibody titres than healthy control patients 21 days after vaccination with BNT162b2.
participants after the second vaccination.(5) • Liver diseases: vaccination is recommended to be given to patients prior to liver transplant or three to six months after. Success of vaccination depends on the staging of chronic liver disease at the time of immunisation.(28, 38-40)
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: